Brought to you by:
WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study completes enrolment
Merit Medical has announced that it has completed enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective, randomized, controlled, multicenter study comparing the Merit WRAPSODY cell-impermeable endoprosthesis (CIE) to percutaneous transluminal angioplasty (PTA)…
EndoAVF found usually less cost effective compared with sAVF
The Society for Clinical Vascular Surgery (SCVS) 50th Annual Symposium (25–29 March, Miami) hosted a series of abstract presentations. Among them was one by Bianca Mulaney, MD and colleagues including Elizabeth George, MD, Stanford University, Stanford, on the cost effectiveness…
The top 10 most popular Vascular Specialist stories of April 2023
In April 2023, Vascular Specialist readers were drawn to an interview dissecting the role robotics play, and can play in the future, in vascular surgery; a report of a new study that trialled the explantation of mature arteriovenous fistulas (AVFs)…
A call to arms: Reuse of mature venous conduits urged
“Recycle that vein!”—that was the appeal from the authors of a new study that trialled the explantation of mature arteriovenous fistulas (AVFs) from patients with venous outflow obstruction in one extremity and translocation of them to the contralateral extremity. Led…
The top 10 most popular Vascular Specialist stories in March
Among the posts catching Vascular Specialist readers’ eyes last month were the digital flipbook version of our March print edition, a new study looking at the Society for Vascular Surgery (SVS) open abdominal aortic aneurysm (AAA) recommendations, and an interview…
Select gene SNPs found to be associated with venous ulcer formation and persistence
Looking to the future, genetic testing may play a role in guiding the intensity of therapeutic interventions and preventive strategies in patients with venous disease. This finding comes from a case-control study on the clinical implications of genetic variation of…
AVF 2022: Emerging autogenous venous valve formation system sees ‘continual improvement’
An emerging endovenous valve formation system designed to treat patients with chronic venous insufficiency (CVI) with evidence of deep venous reflux has demonstrated continual improvement since U.S. investigators started performing clinical cases with the device 18 months ago, according to…
AVF 2022: Six-month CLOUT data indicate ClotTriever can effectively remove full spectrum of thrombus
Six-month outcomes from the ongoing CLOUT registry demonstrate the “safety and efficacy” of the ClotTriever thrombectomy system in a real-world deep vein thrombosis (DVT) population regardless of clot chronicity level, the 2022 annual meeting of the American Venous Forum (AVF)…
AVF 2022: VenoValve improvement ‘maintained’ for 2.5 years without adverse events
Envveno Medical announced positive 30-month data from the first-in-human trial of the VenoValve bioprosthetic potential venous valve replacement during the 2022 American Venous Forum (AVF) annual meeting (VENOUS2022) held in Orlando, Florida (Feb. 23–26). The results showed that VenoValve recipients—now an…
Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data
The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term data suggesting it offers an “excellent alternative” to AVF creation via surgical procedures in end-stage renal…